Liver cancer organoids used to screen over 1,600 potential treatments

Researchers at the University of Basel have utilized a biobank of 35 hepatocellular carcinoma organoids to screen more than 1,600 compounds. This approach has identified drug combinations that demonstrate selective anti-tumor activity across diverse liver cancer types. The study highlights the potential of organoid models in advancing personalized cancer treatment.

Originally published by gnews